Oral Vaccine Advantage Mazen focuses on oral vaccines delivered via animal feed using corn seed, offering safer administration, reduced handling, and potential improvements in ROI by removing the economic thresholds of injectable vaccines. Sales opportunities exist with feed manufacturers, large-scale dairy, poultry, and swine operations seeking easier vaccination programs and better worker safety.

Ambient Stability The platform’s ambient temperature stability enables global reach without cold chain constraints, creating sales potential in remote or developing markets and reducing logistics costs for distributors and integrators in the animal health supply chain.

Proof of Efficacy Two vaccine candidates with proven efficacy data position Mazen to engage R&D and regulator-facing teams, enabling partnerships or licensing discussions with mid to large biotech or pharma players seeking innovative subunit vaccines and novel delivery methods.

Strategic Hires Recent senior recruitment in breeding signals a focus on genetic and manufacturing optimization, presenting opportunities to partner with commercial breeders, contract manufacturers, and ingredient suppliers to align on vaccine traits, stability, and scalable production.

Growth Financing The company has meaningful but modest revenue and former funding rounds, suggesting room for strategic co-investment, grant programs, and collaboration with investors or corporate partners to accelerate product development, regulatory approvals, and market entry in targeted species and regions.